Boundless Total Other Income Expense Net from 2010 to 2026
| BOLD Stock | USD 1.15 0.02 1.77% |
Total Other Income Expense Net | First Reported 2016-09-30 | Previous Quarter 1.4 M | Current Value 1.3 M | Quarterly Volatility 1.7 M |
Check Boundless Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Boundless Bio's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.9 M, Selling General Administrative of 11.9 M or Other Operating Expenses of 55.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.31. Boundless financial statements analysis is a perfect complement when working with Boundless Bio Valuation or Volatility modules.
Boundless | Total Other Income Expense Net | Build AI portfolio with Boundless Stock |
Analyzing Boundless Bio's Total Other Income Expense Net over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Total Other Income Expense Net has evolved provides context for assessing Boundless Bio's current valuation and future prospects.
Latest Boundless Bio's Total Other Income Expense Net Growth Pattern
Below is the plot of the Total Other Income Expense Net of Boundless Bio Common over the last few years. It is Boundless Bio's Total Other Income Expense Net historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Boundless Bio's overall financial position and show how it may be relating to other accounts over time.
| Total Other Income Expense Net | 10 Years Trend |
|
Total Other Income Expense Net |
| Timeline |
Boundless Total Other Income Expense Net Regression Statistics
| Arithmetic Mean | 2,448,864 | |
| Geometric Mean | 744,780 | |
| Coefficient Of Variation | 142.79 | |
| Mean Deviation | 2,965,454 | |
| Median | 378,000 | |
| Standard Deviation | 3,496,679 | |
| Sample Variance | 12.2T | |
| Range | 9.5M | |
| R-Value | 0.72 | |
| Mean Square Error | 6.3T | |
| R-Squared | 0.52 | |
| Significance | 0 | |
| Slope | 497,816 | |
| Total Sum of Squares | 195.6T |
Boundless Total Other Income Expense Net History
About Boundless Bio Financial Statements
Boundless Bio stakeholders use historical fundamental indicators, such as Boundless Bio's Total Other Income Expense Net, to determine how well the company is positioned to perform in the future. Although Boundless Bio investors may analyze each financial statement separately, they are all interrelated. For example, changes in Boundless Bio's assets and liabilities are reflected in the revenues and expenses on Boundless Bio's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Boundless Bio Common. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Other Income Expense Net | 9.1 M | 9.5 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Boundless Bio Common is a strong investment it is important to analyze Boundless Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Boundless Bio's future performance. For an informed investment choice regarding Boundless Stock, refer to the following important reports:Check out the analysis of Boundless Bio Correlation against competitors. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Will Biotechnology sector continue expanding? Could Boundless diversify its offerings? Factors like these will boost the valuation of Boundless Bio. Projected growth potential of Boundless fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Boundless Bio data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Boundless Bio Common is measured differently than its book value, which is the value of Boundless that is recorded on the company's balance sheet. Investors also form their own opinion of Boundless Bio's value that differs from its market value or its book value, called intrinsic value, which is Boundless Bio's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Boundless Bio's market value can be influenced by many factors that don't directly affect Boundless Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Boundless Bio's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Boundless Bio should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Boundless Bio's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.